Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500182 | 0.85 | KDM4E (0.71) | KDM4EALDH1A1MAPTHSD17B10LMNA | |
| SCHEMBL2104383 | 0.83 | ALDH1A1 (0.76) | KDM4EALDH1A1MAPTHSD17B10LMNA | |
| SCHEMBL29857922 | 0.82 | PLD1 (0.73) | KDM4EALDH1A1MAPTHSD17B10POLB | |
| SCHEMBL21353591 | 0.82 | — | — | |
| SCHEMBL15800694 | 0.82 | PLD1 (0.73) | KDM4EALDH1A1MAPTHSD17B10POLB | |
| SCHEMBL4324132 | 0.81 | KDM4E (0.79) | KDM4EALDH1A1MAPTHSD17B10LMNA | |
| SCHEMBL13149496 | 0.80 | KDM4E (0.68) | KDM4EALDH1A1MAPTHSD17B10LMNA | |
| SCHEMBL2963306 | 0.77 | ALDH1A1 (0.68) | KDM4EALDH1A1MAPTHSD17B10LMNA | |
| SCHEMBL1371533 | 0.77 | PLD1 (0.61) | KDM4EALDH1A1MAPTHSD17B10POLB | |
| SCHEMBL5251477 | 0.76 | KDM4E (0.76) | KDM4EALDH1A1MAPTHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819667-B1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8163735-B2 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | CTSF, CTSS, CSTB | KDM4E 2963/4885ALDH1A1 2409/4885MAPT 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.